AXLRx Book a callCommission

Big Pharma · Metabolic

Eli Lilly — Metabolic

Eli Lilly across Metabolic: the full competitive set, and the 3 AXLRx reports mapping the competitive, patient-flow and payer picture — each scoped to a single asset and cited to a live source.

Commission a Eli Lilly report

By therapy area

Therapy area All areas NeurologyImmunologyMetabolic

Market All United States

AXLRx reports featuring Eli Lilly — Metabolic

CI · Metabolic · CI Team · Launch Lead US Obesity Competitive Intelligence Tirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality. US · In-Market · Read report → CI · Metabolic · CI Team · Launch Lead US Type 2 Diabetes Competitive Intelligence Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access. US · In-Market · Read report → DL · Metabolic · CI Team · Launch Lead US Obesity Disease Landscape US adult obesity at 41.9% (CDC NHANES). BMI-class distribution, severe-obesity burden, and the comorbidity segments that drive coverage. US · In-Market · Read report →